Skip to Content
Morningstar

Intensity Therapeutics Inc INTS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$4.42 +0.42 (10.50%)
View Full Chart
As of Delayed Price Post-Trading: —
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
INTS is trading within a range we consider fairly valued.
Price
$3.98
Fair Value
$6.00
Uncertainty
Extreme
1-Star Price
$71.59
5-Star Price
$6.74
Economic Moat
Pfc
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INTS is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$4.00
Day Range
$4.06–4.75
52-Week Range
$2.01–11.44
Bid/Ask
$4.42 / $4.46
Market Cap
$60.61 Mil
Volume/Avg
124,175 / 36,962

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
17
Website
https://www.intensitytherapeutics.com

Comparables

Valuation

View More
Metric
INTS
MRSN
TYRA
Price/Earnings (Normalized)
 ———
Price/Book Value
 5.6411.462.49
Price/Sales
 —8.18—
Price/Cash Flow
 ———
Price/Earnings
INTS
MRSN
TYRA

Financial Strength

Metric
INTS
MRSN
TYRA
Quick Ratio
 4.173.4313.27
Current Ratio
 4.433.5113.80
Interest Coverage
 −63.38−34.91—
Quick Ratio
INTS
MRSN
TYRA

Profitability

Metric
INTS
MRSN
TYRA
Return on Assets (Normalized)
 −70.79%−41.22%−21.92%
Return on Equity (Normalized)
 −122.51%−196.75%−23.10%
Return on Invested Capital (Normalized)
 −111.10%−129.55%−27.33%
Return on Assets
INTS
MRSN
TYRA
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKzjlzwnjnrWqjq$585.2 Bil
VRTX
Vertex Pharmaceuticals IncFxyfkdgfWpcnds$110.9 Bil
REGN
Regeneron Pharmaceuticals IncPdtgjmbsWtjvn$107.6 Bil
MRNA
Moderna IncVbgtzdtcCzprl$48.2 Bil
BNTX
BioNTech SE ADRCtprtdvnTkxy$22.3 Bil
ARGX
argenx SE ADRHvpjzfrmMtr$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncGgdzpqtjXjccs$19.0 Bil
BMRN
Biomarin Pharmaceutical IncWhkldcmVgqbs$15.3 Bil
INCY
Incyte CorpCvjmxxbVfctkxj$13.0 Bil
RPRX
Royalty Pharma PLC Class AKpkspdggfYmnwqd$12.8 Bil

Sponsor Center